CCO Treatment Updates

Treatment of Chronic Myeloid Leukemia

Module

Current Treatment Options for Chronic Myelogenous Leukemia

Faculty:
Hagop M. Kantarjian, MD Jorge E. Cortes, MD Elias Jabbour, MD

CME CREDIT INFORMATION

Release Date: 12/12/06

Expiration Date: 12/11/07

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Hagop Kantarjian, MD; Elias Jabbour, MD; and Jorge Cortes, MD, review the current standard of care for chronic myelogenous leukemia as well as novel therapies in clinical development.

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe optimal initial treatment strategies for chronic myelogenous leukemia (CML)
Discuss laboratory tests used to monitor responses in patients with CML being treated with imatinib therapy
Discuss treatment options for patients with CML who are resistant to or intolerant of imatinib therapy

Interactive Case Challenges

Management of a 50-Year-Old Female With High-Risk CML

Faculty:
Elias Jabbour, MD Hagop M. Kantarjian, MD

CME CREDIT INFORMATION

Release Date: 01/11/07

Expiration Date: 01/10/08

Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Test your ability to manage a patient who has chronic myeloid leukemia with high-risk features.

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe optimal initial treatment strategies for CML
Discuss the role of higher imatinib doses in the management of high-risk chronic-phase CML
Describe appropriate management of a patient with chronic-phase CML in cytogenetic relapse following initial response to treatment with imatinib

A 45-Year-Old Woman With CML Who Is Intolerant of Imatinib

Faculty:
Martin S. Tallman, MD Olga Frankfurt, MD

CME CREDIT INFORMATION

Release Date: 01/12/07

Expiration Date: 01/11/08

Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Test your ability to manage a previously healthy 45-year-old female who experiences malaise, fatigue, and weight loss and is subsequently diagnosed with Philadelphia chromosome–positive (Ph+) chronic myelogenous leukemia (CML) in chronic phase.

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe optimal initial treatment strategies for CML
Explain options for management of patients who are initially intolerant of standard imatinib first-line therapy
Describe optimal treatment approaches to patient who experience hematologic relapse following first-line imatinib therapy

Management of a 39-Year-Old Male With Intermediate-Risk, Chronic-Phase CML

Faculty:
Michael W.N. Deininger, MD, PhD

CME CREDIT INFORMATION

Release Date: 12/12/06

Expiration Date: 12/11/07

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Test your ability to manage newly diagnosed chronic-phase CML in a younger patient classified as high risk according to the Sokal scoring system.

Learning Objectives

Upon completion of this activity, participants should be able to:

Review the use of imatinib in the frontline treatment of chronic-phase CML
Discuss allogeneic hematopoietic stem cell transplant in the setting of chronic-phase CML
Discuss appropriate uses of dasatinib in the treatment of chronic-phase CML

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.